Scpharmaceuticals (NASDAQ:SCPH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Thursday, Zacks.com reports.

According to Zacks, “scPharmaceuticals, Inc., is a biopharmaceutical company. It engaged in developing pharmaceutical products for subcutaneous delivery. The Company’s pipeline programs include: scFurosemide lead product candidate, Furoscix, consists of its proprietary subcutaneous formulation of furosemide delivered via sc2Wear Infusor for diuresis in heart failure patients outside of the acute care setting. scPharmaceuticals, Inc., is based in BURLINGTON, United States. “

Several other equities analysts have also issued reports on SCPH. Leerink Swann lowered shares of Scpharmaceuticals from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $12.00 to $5.00 in a report on Wednesday, January 30th. Svb Leerink lowered shares of Scpharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 30th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $8.56.

Shares of SCPH stock opened at $2.75 on Thursday. The company has a market cap of $51.10 million, a P/E ratio of -1.73 and a beta of 1.18. The company has a debt-to-equity ratio of 0.10, a quick ratio of 13.77 and a current ratio of 13.77. Scpharmaceuticals has a 52-week low of $2.70 and a 52-week high of $15.70.

Scpharmaceuticals (NASDAQ:SCPH) last issued its quarterly earnings data on Thursday, March 21st. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.44) by $0.17. Sell-side analysts anticipate that Scpharmaceuticals will post -2.07 earnings per share for the current fiscal year.

An institutional investor recently raised its position in Scpharmaceuticals stock. JPMorgan Chase & Co. raised its position in Scpharmaceuticals Inc (NASDAQ:SCPH) by 1,268.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 22,664 shares of the company’s stock after acquiring an additional 21,008 shares during the period. JPMorgan Chase & Co. owned approximately 0.12% of Scpharmaceuticals worth $133,000 as of its most recent filing with the Securities & Exchange Commission. 42.24% of the stock is currently owned by institutional investors.

Scpharmaceuticals Company Profile

scPharmaceuticals Inc, a clinical-stage pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix, a drug-device combination product that is under development for treatment of worsening or decompensated heart failure outside of the inpatient setting.

Recommended Story: What are gap-down stocks?

Get a free copy of the Zacks research report on Scpharmaceuticals (SCPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.